Total of reported cases (n) |
(n=3) |
(n=9) |
(n=1) |
(n=2) |
(n=2) |
Age (Mean ± SD) |
48.6 ± 21.45 years |
46.3 ± 26.79 years |
41 years |
40.5 ± 11.5 years |
60 ± 12 years |
Gender n (%)
Female (F)
Male (M)
|
F: 2 (66.67 %)
M: 1 (33.33 %)
|
F: 7 (77.77 %)
M: 2(22.22 %)
|
M: 1 (100 %)
|
F: 1 (50 %)
M: 1 (50 %)
|
F: 1 (50 %)
M: 1 (50 %)
|
Time to symptom onset (Mean ± SD) |
10.3 ± 12.49 days |
13.97 ± 28.82
days |
1 day |
28 ± 20 hours |
15 ± 9 hours |
Background/comorbidities n (%) (n=17)
|
Present: 8 (47.06 %)
Not present: 9 (52.94 %)
|
Present: 8 (47.06 %)
Not present: 9 (52.94 %)
|
Present: 8 (47.06 %)
Not present: 9 (52.94 %)
|
Present: 8 (47.06 %)
Not present: 9 (52.94 %)
|
Present: 8 (47.06 %)
Not present: 9 (52.94 %)
|
Test COVID-19 n (%) (n=17)
|
Positive: 0 (0.0 %)
Negative: 11 (64.71 %)
Not described: 6 (35.29 %)
|
Positive: 0 (0.0 %)
Negative: 11 (64.71 %)
Not described: 6 (35.29 %)
|
Positive: 0 (0.0 %)
Negative: 11 (64.71 %)
Not described: 6 (35.29 %)
|
Positive: 0 (0.0 %)
Negative: 11 (64.71 %)
Not described: 6 (35.29 %)
|
Positive: 0 (0.0 %)
Negative: 11 (64.71 %)
Not described: 6 (35.29 %)
|
Type of COVID-19 vaccine n (%) (n=17)
|
Pfizer-BioNTech (mRNA): 11 (64.71 %)
Modern (mRNA): 2 (11.76 %)
BBIBP-CorV (Sinopharm):2 (11.76 %)
Johnson & Johnson / Jassen vaccine (Viral vector): 2 (11.76 %)
|
Pfizer-BioNTech (mRNA): 11 (64.71 %)
Modern (mRNA): 2 (11.76 %)
BBIBP-CorV (Sinopharm):2 (11.76 %)
Johnson & Johnson / Jassen vaccine (Viral vector): 2 (11.76 %)
|
Pfizer-BioNTech (mRNA): 11 (64.71 %)
Modern (mRNA): 2 (11.76 %)
BBIBP-CorV (Sinopharm):2 (11.76 %)
Johnson & Johnson / Jassen vaccine (Viral vector): 2 (11.76 %)
|
Pfizer-BioNTech (mRNA): 11 (64.71 %)
Modern (mRNA): 2 (11.76 %)
BBIBP-CorV (Sinopharm):2 (11.76 %)
Johnson & Johnson / Jassen vaccine (Viral vector): 2 (11.76 %)
|
Pfizer-BioNTech (mRNA): 11 (64.71 %)
Modern (mRNA): 2 (11.76 %)
BBIBP-CorV (Sinopharm):2 (11.76 %)
Johnson & Johnson / Jassen vaccine (Viral vector): 2 (11.76 %)
|
Dose n (%) (n=17)
|
First dose: 9 (52.94 %)
Second dose: 4 (23.53 %)
Third dose: 4 (23.53 %)
|
First dose: 9 (52.94 %)
Second dose: 4 (23.53 %)
Third dose: 4 (23.53 %)
|
First dose: 9 (52.94 %)
Second dose: 4 (23.53 %)
Third dose: 4 (23.53 %)
|
First dose: 9 (52.94 %)
Second dose: 4 (23.53 %)
Third dose: 4 (23.53 %)
|
First dose: 9 (52.94 %)
Second dose: 4 (23.53 %)
Third dose: 4 (23.53 %)
|
Symptoms n (%) (n=17)
|
Abdominal pain: 14 (82.35 %)
Nausea: 10 (58.82 %)
Vomiting: 7 (41.18 %)
Fever: 3 (17.64 %)
Epigastric pain: 3 (17.64 %)
Shivering: 2 (11.76 %)
Loss appetite: 2 (11.76 %)
Diarrhea: 2 (11.76 %)
Sweating: 1 (5.88 %)
Dark colored urine: 1 (5.88 %)
Hemoptysis: 1 (5.88 %)
Aphagia: 1 (5.88 %)
Constipation: 1 (5.88 %)
Anuria: 1 (5.88 %)
Hematochezia: 1 (5.88 %)
Fatigue: 1 (5.88 %)
Erythematous maculopapular rashes: 1 (5.88 %)
|
Abdominal pain: 14 (82.35 %)
Nausea: 10 (58.82 %)
Vomiting: 7 (41.18 %)
Fever: 3 (17.64 %)
Epigastric pain: 3 (17.64 %)
Shivering: 2 (11.76 %)
Loss appetite: 2 (11.76 %)
Diarrhea: 2 (11.76 %)
Sweating: 1 (5.88 %)
Dark colored urine: 1 (5.88 %)
Hemoptysis: 1 (5.88 %)
Aphagia: 1 (5.88 %)
Constipation: 1 (5.88 %)
Anuria: 1 (5.88 %)
Hematochezia: 1 (5.88 %)
Fatigue: 1 (5.88 %)
Erythematous maculopapular rashes: 1 (5.88 %)
|
Abdominal pain: 14 (82.35 %)
Nausea: 10 (58.82 %)
Vomiting: 7 (41.18 %)
Fever: 3 (17.64 %)
Epigastric pain: 3 (17.64 %)
Shivering: 2 (11.76 %)
Loss appetite: 2 (11.76 %)
Diarrhea: 2 (11.76 %)
Sweating: 1 (5.88 %)
Dark colored urine: 1 (5.88 %)
Hemoptysis: 1 (5.88 %)
Aphagia: 1 (5.88 %)
Constipation: 1 (5.88 %)
Anuria: 1 (5.88 %)
Hematochezia: 1 (5.88 %)
Fatigue: 1 (5.88 %)
Erythematous maculopapular rashes: 1 (5.88 %)
|
Abdominal pain: 14 (82.35 %)
Nausea: 10 (58.82 %)
Vomiting: 7 (41.18 %)
Fever: 3 (17.64 %)
Epigastric pain: 3 (17.64 %)
Shivering: 2 (11.76 %)
Loss appetite: 2 (11.76 %)
Diarrhea: 2 (11.76 %)
Sweating: 1 (5.88 %)
Dark colored urine: 1 (5.88 %)
Hemoptysis: 1 (5.88 %)
Aphagia: 1 (5.88 %)
Constipation: 1 (5.88 %)
Anuria: 1 (5.88 %)
Hematochezia: 1 (5.88 %)
Fatigue: 1 (5.88 %)
Erythematous maculopapular rashes: 1 (5.88 %)
|
Abdominal pain: 14 (82.35 %)
Nausea: 10 (58.82 %)
Vomiting: 7 (41.18 %)
Fever: 3 (17.64 %)
Epigastric pain: 3 (17.64 %)
Shivering: 2 (11.76 %)
Loss appetite: 2 (11.76 %)
Diarrhea: 2 (11.76 %)
Sweating: 1 (5.88 %)
Dark colored urine: 1 (5.88 %)
Hemoptysis: 1 (5.88 %)
Aphagia: 1 (5.88 %)
Constipation: 1 (5.88 %)
Anuria: 1 (5.88 %)
Hematochezia: 1 (5.88 %)
Fatigue: 1 (5.88 %)
Erythematous maculopapular rashes: 1 (5.88 %)
|
Treatment n (%) (n=17)
|
Medical: 15 (88.34 %)
Surgical: 2 (11.76 %)
|
Medical: 15 (88.34 %)
Surgical: 2 (11.76 %)
|
Medical: 15 (88.34 %)
Surgical: 2 (11.76 %)
|
Medical: 15 (88.34 %)
Surgical: 2 (11.76 %)
|
Medical: 15 (88.34 %)
Surgical: 2 (11.76 %)
|